RCS - Arecor Therapeutics - ARECOR TO HOST KOL WEBINAR

Arecor TherapeuticsAnnouncement

18/05/2022 08:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220518:nRSR8494La&default-theme=true

RNS Number : 8494L  Arecor Therapeutics PLC  18 May 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING
INSULIN TREATMENTS IN DIABETES CARE

 

Cambridge, UK, 18 May 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it will host a key opinion leader webinar entitled "The
Need for Concentrated and Rapid Acting Insulin Treatments in Diabetes Care",
on Thursday 26 May, 2022, at 15:00-16:30 BST.

 

The virtual event will explore the treatment challenges for the growing number
of people living with diabetes, particularly those with type 2 diabetes, who
require high daily doses of insulin to maintain their blood glucose within
their target range. While rapid acting insulins have become standard of care,
there are currently no concentrated rapid acting insulin products available to
patients to enable reduced injection volumes, fewer injections per day and the
potential for improved blood glucose control.

 

Arecor is developing a novel insulin product candidate, AT278, which uniquely
combines two key characteristics: an ultra-rapid onset of action which is
critical for postprandial glucose control and an ultra-concentrated
formulation to enable reduced injection volumes and fewer injections per day.
Data from a Phase I clinical trial of AT278, recently presented at the 15(th)
International Advanced Technologies and Treatments for Diabetes (ATTD)
meeting, showed that AT278 exhibited an accelerated pharmacokinetic (PK) and
pharmacodynamic (PD) profile when compared to NovoRapid®, a gold standard
prandial insulin treatment, despite a 5-fold increase in concentration.

 

Arecor's webinar will bring together four world-class experts in the field of
diabetes care, who will discuss the AT278 clinical data as well as the
clinical and patient need. The event will be moderated by Jay Skyler,
Professor of Medicine, Pediatrics & Psychology, in the Division of
Endocrinology Diabetes & Metabolism at the University of Miami, USA.

 

·    Wendy Lane, Clinical Endocrinologist, Director of Clinical Research,
Mountain Diabetes and Endocrine Center, Asheville, USA, will discuss the
increasing need for rapid-acting concentrated insulin products for people
living with Type 2 diabetes from a clinical perspective.

·    Davida Kruger, Certified Diabetes Nurse Practitioner, Henry Ford
Health System, Division of Endocrinology, Detroit, USA, will focus on the
benefits of concentrated insulin from the patient perspective.

 

·    Thomas Pieber, Head of the Division of Endocrinology and Metabolism
at the Medical University of Graz, Austria, will summarise the results from
Arecor's Phase I clinical trial of its ultra-rapid, ultra-concentrated insulin
product candidate, AT278.

 

The presentations will be followed by a live Q&A session.

 

To register for the event on the Advanced Technologies & Treatment for
Diabetes (ATTD) Educational Portal click here
(https://us02web.zoom.us/webinar/register/WN_3pQ8F6y_T7aInDvozaif_g?utm_source=Marketo&utm_medium=email&mkt_tok=MzA1LVFVSy01MTkAAAGEaxbcwGBJZSh6xWseH5LooODRfzL4uC6xol7s2z9Aobhzcqicu5sCWJWkumC8yj6Sdo6QXo-bbxEeFa3Rlsk)
.

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRGDUCBBDGDR